- Topic
13k Popularity
10k Popularity
10k Popularity
50k Popularity
5k Popularity
33k Popularity
22k Popularity
34k Popularity
150k Popularity
- Pin
- GT Airdrop Is Live! 1.92M GT Burned in Q2, Worth Over $39M
🎁 Complete simple tasks, get up to 13.2 GT per user
📅 From July 8 to July 20
👉 Join now + trade futures to qualify: https://www.gate.com/campaigns/1431
- 📢 #Gate Square Writing Contest Phase 1# is now officially launched!
Share your unique insights on the CROSS project and stand a chance to win $500 worth of CROSS rewards!
💰 Rewards:
1st Prize (1 winner): $150 worth of CROSS
2nd Prize (3 winners): $50 worth of CROSS each
3rd Prize (10 winners): $20 worth of CROSS each
👉 How to Participate:
1. Publish your unique insights on the CROSS project in Gate Square.
2. Add the tag #Gate Square Writing Contest Phase 1# to your post (minimum of 300 words).
3. Share your article or insights on X with the tags: Gate Square & CROSS.
Essay Content Directio
- 🎉 #Gate xStocks Trading Share# Posting Event Is Ongoing!
📝 Share your trading experience on Gate Square to unlock $1,000 rewards!
🎁 5 top Square creators * $100 Futures Voucher
🎉 Share your post on X – Top 10 posts by views * extra $50
How to Participate:
1️⃣ Follow Gate_Square
2️⃣ Make an original post (at least 20 words) with #Gate xStocks Trading Share#
3️⃣ If you share on Twitter, submit post link here: https://www.gate.com/questionnaire/6854
Note: You may submit the form multiple times. More posts, higher chances to win!
📅 End at: July 9, 16:00 UTC
Show off your trading on Gate Squ
- 🚀 Calling all Gate Square content creators!
Join the Gate 2025 Mid-Year Gala to become a top creator
Win Gate x Red Bull merch, $1,000 Futures Vouchers, VIP+1, and fan-exclusive rewards!
Sign up now 👉 www.gate.com/activities/community-vote
#GateSquare#
Fudan Zhangjiang: The price reduction of Doxorubicin Liposome Injection is not less than 35%.
Jin10 News on April 30, Fudan Zhangjiang announced that the company has decided to adjust the market retail price of Doxorubicin Liposome Injection starting from May 1, 2025, with a price reduction of no less than 35% compared to the previous bidding price. The sales revenue of this drug in 2024 is expected to be approximately 210 million RMB, accounting for 29% of the company's total annual sales revenue. The price adjustment is expected to have an adverse impact on the company's sales revenue for 2025 and the subsequent execution period, potentially leading to a risk of single-product losses for this drug in 2025.